Pulmonary vascular disease & thromboembolismSecondary analysis
Extended Low-Dose Apixaban and Superficial Vein Thrombosis
- Secondary analysis of the HI-PRO randomised trial
- post hoc analysis
Study context
- Population
- Patients with provoked VTE and enduring risk factors
- Comparison
- Extended low-dose apixaban
- Primary endpoint
- Symptomatic superficial vein thrombosis events
Original publication
Extended Low-Dose Apixaban and Superficial Vein Thrombosis. JAMA Cardiol. Published 1 May 2026. doi:10.1001/jamacardio.2026.0151
Summarised from the published abstract; every number is checked against it